Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 58

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 58
---
        123                366  
  At 31 December 2022                                                   1,108      83,667      53,003      720      ( 135,336        3,162  

  F-13  

  Table of Contents  

Biodexa Pharmaceuticals PLC

Annual Report 2024

Notes forming part of the financial statements

For the years ended 31 December 2024, 2023 and 2022

1 Accounting policies

General information

Biodexa Pharmaceuticals PLC (the ‘ Company’) is a company registered and
domiciled in England and Wales. The Company was incorporated on 12 September 2014.

The Company is a public limited company, whose ordinary shares were admitted to trading
on AIM (‘ AIM’), which is a submarket of the London Stock Exchange, on 8 December 2014 until admission of the Company’s
ordinary shares to trading on AIM was cancelled 26 April 2023.

In addition, since 4 December 2015 the Company has American Depository Receipts (‘ ADRs’)
registered with the US Securities and Exchange Commission (‘ SEC’) and is listed on the NASDAQ Capital Market.

The financial statements were approved and authorised for issue by the Board of Directors
on 10 April 2025.

Basis of preparation

The Group was formed on 31 October 2014 when the Company entered into an agreement
to acquire the entire share capital of Biodexa Limited and its wholly owned subsidiaries through the issue equivalent of shares in the
Company which took place on 13 November 2014.

These financial statements have been prepared in accordance with International Financial
Reporting Standards as issued by the International Accounting Standards Board (IASB).

The principal accounting policies adopted in the preparation of the financial statements
are set out below. The policies have been consistently applied to all the periods presented.

The consolidated financial statements have been prepared on a historical cost basis,
except for the following item (refer to individual accounting policies for details):

  Certain financial instruments – fair value through profit  

Adoption of new and revised standards

New standards, interpretations and amendments effective from 1 January 2024

The Group reviewed the new standards, interpretations and amendments effective from
1 January 2024 and deemed none were applicable to the annual financial statements for the year ended 31 December 2024.

New standards, interpretations and amendments
not yet effective

There are a number of standards, amendments to
standards